Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market
The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.
You may also be interested in...
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Janssen-Cilag has withdrawn the EU marketing application for the IL-6 inhibitor sirukumab, with the CHMP saying the long-term safety of sirukumab had not been well characterized and further clinical studies were required, a conclusion also drawn earlier by the US FDA.
Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.